Atlas Trials

Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Clinical trial NCT04313660 · UNKNOWN

Trial details

NCT number
NCT04313660
Sponsor
Xiaorong Dong
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLCAnlotinibPD-1/L1 Inhibitor
Start date
2020-04-01
Primary completion
2021-02-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.